A retrospective review of dupilumab for atopic dermatitis patients with allergic contact dermatitis
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There have been multiple reports demonstrating the effectiveness of dupilumab in the treatment of ACD.
“There have been multiple reports demonstrating the effectiveness of dupilumab in the treatment of ACD (eTable).[12][13][14][15][16][17][18][19][20]”
From Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing. (2022) · cites this paper as [17]
Findings from these studies show that dupilumab can improve recalcitrant dermatitis caused by a broad range of contact allergens, including nickel.
“The findings from these studies show that dupilumab can improve recalcitrant dermatitis caused by a broad range of contact allergens, including nickel.”
From Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing. (2022) · cites this paper as [17]
Cites
Weidinger, S., & Novak, N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00149-x · Cited by 1,908 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing.
Johnson, H. (2022) · Current Psychiatry · doi:10.12788/cutis.0519 · Cited by 20 · see citing works
- Authors
- Chipalkatti, N., Lee, N., Zancanaro, P., Dumont, N., Kachuk, C., & Rosmarin, D.
- Affiliations
- Tufts University (US)
- Tufts Medical Center (US)
- Corresponding author
- Rosmarin, David
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 80
- Issue
- 4
- Pages
- 1166-1167
- ISSN
- 0190-9622 (ISSN-L)
- OpenAlex
- W2909337324
- Cited by
- 34
- References
- 1
- Citations by year
- 2025: 3 · 2024: 1 · 2023: 7 · 2022: 7 · 2021: 5 · 2020: 5 · 2019: 6
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of the American Academy of Dermatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
- Keywords
- dupilumab, atopic dermatitis, allergic contact dermatitis, Th2 pathway, IL-4 receptor alpha blockade, IL-13, IL-22, cytokines, delayed-type hypersensitivity
- MeSH terms
- Adult, Antibodies, Monoclonal, Dermatitis, Atopic, Dermatologic Agents, Female, Humans, Male, Middle Aged, Retrospective Studies, Dermatitis, Allergic Contact, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
